Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives

Background: The clinical evaluation of HER2CLIMB trial showed a 21. 9-month median overall survival with the triplet regimens of tucatinib, capecitabine, and trastuzumab (TXT) for patients with human epidermal growth factor receptor 2 (HER2) –overexpressing metastatic breast cancer. From the payer&#...

Full description

Bibliographic Details
Main Authors: Qiuji Wu, Weiting Liao, Mengxi Zhang, Jiaxing Huang, Pengfei Zhang, Qiu Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Oncology
Subjects:
tucatinib
metastatic breast cancer
HER2-positive
cost-effectiveness
Markov model
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01336/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01336/full

Similar Items